stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Book value per share
Xencor, Inc.'s book value per share at the end of fiscal 2025 was 8.6×, down 17.4% from 10.4× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 6.6×. Over the past ten years it has ranged from 4.2× (fiscal 2015) to 12.6× (fiscal 2021); the current reading is higher than 36% of that period. Xencor, Inc. ranks 119th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 8.6× | (17.39%) |
| FY2024 | 10.4× | (5.30%) |
| FY2023 | 10.9× | (10.27%) |
| FY2022 | 12.2× | (2.93%) |
| FY2021 | 12.6× | 25.57% |
| FY2020 | 10.0× | (4.65%) |
| FY2019 | 10.5× | 8.50% |
| FY2018 | 9.7× | 43.07% |
| FY2017 | 6.8× | (11.15%) |
| FY2016 | 7.6× | 82.74% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 6.6× | (3.19%) |
| Mar 2026 | 6.9× | (19.96%) |
| Dec 2025 | 8.6× | 1.88% |
| Sep 2025 | 8.4× | 0.62% |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BEAM Beam Therapeutics Inc. compare | 9.1× |
| MBX MBX Biosciences, Inc. compare | 8.6× |
| XNCR Xencor, Inc. | 6.6× |
| PHVS Pharvaris N.V. compare | 5.1× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 5.1× |
| RCUS Arcus Biosciences, Inc. compare | 2.8× |
| ADMA ADMA Biologics Inc compare | 2.0× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 1.7× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement